HC Wainwright & Co. Reiterates Buy on Lineage Cell Therapeutics, Maintains $7 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis reiterated a Buy rating on Lineage Cell Therapeutics (LCTX) and maintained a $7 price target. This reaffirms the firm's positive outlook on the company.
February 13, 2024 | 5:38 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. reaffirmed a Buy rating on Lineage Cell Therapeutics with a $7 price target, indicating a strong positive outlook on the company's future.
The reiteration of a Buy rating and maintenance of a $7 price target by a reputable analyst firm like HC Wainwright & Co. typically signals a strong vote of confidence in the company's prospects. This can positively influence investor sentiment and potentially lead to an increase in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100